Beijing, China

Falong Jiang



 

Average Co-Inventor Count = 12.3

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2018-2020

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: Inventor Spotlight: Falong Jiang from Beijing, CN

Introduction

Falong Jiang is an innovative inventor based in Beijing, China, known for his contributions to the field of pharmaceuticals. With a total of three patents to his name, he has made significant strides in developing compounds that can impact the body’s regulatory functions.

Latest Patents

Falong Jiang's most recent patents include groundbreaking inventions focused on fused pyrazine derivatives. These compounds are useful as soluble guanylate cyclase stimulators, which modulate the body's production of cyclic guanosine monophosphate (cGMP). The first invention provides certain fused pyrazine compounds that can be utilized in the therapy and prophylaxis of diseases linked to disrupted cGMP balance. The pharmaceutical compositions associated with this invention comprise these compounds, showcasing their potential for medical applications. The second patent also revolves around soluble guanylate cyclase stimulators and similar methods for utilizing these compounds in therapeutic approaches.

Career Highlights

Falong Jiang has had a successful career at Merck Sharp & Dohme Corporation, a leading global health company. His work emphasizes his expertise in pharmaceutical research and development, particularly in the area of compounds that interact with cellular signaling mechanisms.

Collaborations

Throughout his career, Falong has worked closely with notable coworkers, including Raphaelle Berger and Joie Garfunkle. Their collaborations have spearheaded advancements in innovations related to guanylate cyclase stimulators and the development of effective therapeutic solutions.

Conclusion

Falong Jiang stands out as a pivotal figure in the realm of pharmaceutical inventions. His patents, centered on modulating cGMP levels, present promising opportunities for the treatment of various diseases. With his continued work at Merck Sharp & Dohme Corporation, he is sure to pave the way for future innovations in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…